Research Scientist, William M. Tierney Center for Health Services Research, Regenstrief Institute
Associate Professor of Urology, Indiana University School of Medicine
Dr. Clint Cary’s research efforts focus on improving the health of patients with urologic cancers through health services and outcomes research in testis, bladder, and kidney cancer. He recently completed a 5-year study funded by the NIH to assess utilization rates of single-dose intravesical chemotherapy in patients with non-muscle invasive bladder cancer in a population-based environment.
He actively publishes on advanced testicular cancer outcomes in numerous high-impact journals and has authored numerous book chapters on the topic of testicular cancer. He has served as a Visiting Professor both nationally and internationally to disseminate his research findings.
He provides direct medical and surgical care, with a specific focus on patients with testicular cancer and bladder cancer. Dr. Cary serves as the Director of Urologic Oncology Research for the Department of Urology, Director of the Urologic Germ Cell Tumor Program, and a member of the American Urological Association (AUA) Young Urologists Committee.
Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer
Role: Primary Investigator
Determine the barriers to intraoperative intravesical chemotherapy and how to effectively develop and implement interventions to increase translation of this best available evidence into clinical practice.